NicOx SA: A Specialist in Ophthalmology and Nitric Oxide-Donating Therapeutics
NicOx S.A. is an international biotechnology and pharmaceutical company, headquartered in Biot, France, with a core focus on the research, development, and commercialization of innovative solutions to maintain vision and improve ocular health. The company operates within the specialized field of ophthalmology, concentrating on treatments for major eye diseases such as glaucoma, ocular hypertension, and ocular inflammation. NicOx's proprietary scientific platform revolves around the therapeutic application of nitric oxide (NO)-donating compounds, a technology that allows a drug to release nitric oxide???a naturally occurring signaling molecule???upon administration. This approach is central to its most significant products and pipeline candidates.
The company's business model involves discovering and developing novel therapeutic candidates through its research platform and then partnering with global pharmaceutical companies to handle the final-stage clinical trials, regulatory approvals, and commercialization of the products. NicOx generates revenue through licensing agreements, milestone payments, and royalties on net sales of its approved products.
Products and Services Offered
NicOx has successfully brought two major products to market through its licensing strategy, which form its commercialized portfolio. It also maintains a robust clinical development pipeline based on its NO-donating technology.
I. Commercialized Products (Licensed and Marketed)
The following products were developed by NicOx and are commercialized by its partners in various global markets:
Description and Mechanism of Action: VYZULTA is a nitric oxide-donating prostaglandin analog. It is a dual-mechanism therapy designed to lower intraocular pressure (IOP). The molecule is metabolized in the eye to two active components: latanoprost acid (a prostaglandin F2? analog that increases uveoscleral outflow) and nitric oxide (NO). The NO component acts to increase aqueous humor outflow through the conventional trabecular meshwork pathway. This dual action provides a potent reduction in IOP.
Indication: VYZULTA is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Commercialization: This product is licensed exclusively worldwide to Bausch + Lomb for development and commercialization.
ZERVIATEŽ (cetirizine ophthalmic solution) 0.24%
Description and Mechanism of Action: ZERVIATE is an ophthalmic solution containing cetirizine, a potent H1-receptor antagonist (antihistamine). It is designed to provide relief from ocular itching.
Indication: ZERVIATE is approved for the treatment of ocular itching associated with allergic conjunctivitis.
Commercialization: ZERVIATE is licensed to multiple partners for commercialization in different geographies, including the United States, China, and the majority of Southeast Asian markets.
II. Pipeline Products (In Clinical Development and Preclinical Stages)
NicOx's development activities focus on advancing its pipeline, led by a second-generation NO-donating compound:
Stage of Development: NCX 470 is NicOx's lead product candidate in its ophthalmic pipeline and has successfully completed its Phase 3 clinical development program in the U.S. and China, which included the Mont Blanc and Denali trials. A separate Phase 3 program is also ongoing in Japan.
Description and Mechanism of Action: NCX 470 is a novel, second-generation NO-donating bimatoprost analog. Similar to VYZULTA, it is designed to release both bimatoprost???a widely used prostaglandin analog for IOP lowering???and nitric oxide (NO) into the eye. This dual-release mechanism targets both the uveoscleral and trabecular meshwork outflow pathways to achieve a potentially superior reduction in IOP compared to current standard-of-care treatments for glaucoma.
Indication: Development is focused on lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Commercialization Status: NicOx has entered into licensing agreements for NCX 470 with partners such as Kowa for the U.S. and most of the world, and Ocumension Therapeutics for China, Korea, and Southeast Asian markets.
Stage of Development: This candidate is in Phase 2b clinical development.
Description and Mechanism of Action: NCX 4251 is a novel, proprietary formulation of fluticasone propionate, an established corticosteroid. The formulation utilizes nanocrystals to deliver the drug directly to the eyelid margin.
Indication: It is being developed for the treatment of acute exacerbations of blepharitis, an inflammatory condition of the eyelid. The development program is also exploring its utility in treating dry eye disease.
Commercialization Status: NCX 4251 has been licensed exclusively to a partner for the Chinese market.
NCX 1728 (NO-Donating PDE5 Inhibitor)
Stage of Development: This is a preclinical-stage candidate.
Indication: It is under evaluation for potential use in glaucoma (including for its potential neuroprotective effects) and for various retinal conditions, representing the long-term application of the company???s NO-donating platform beyond topical IOP-lowering agents.
Core Scientific Platform
The company's competitive advantage and core intellectual property are rooted in its Nitric Oxide (NO)-Donating Research Platform. This platform facilitates the creation of new chemical entities (NCEs) that are single molecules combining a commercially validated therapeutic agent with a nitric oxide-releasing moiety. This results in drugs with dual therapeutic effects, offering the potential for enhanced efficacy, particularly in complex diseases like glaucoma where multiple biological pathways contribute to the pathology. The platform specifically aims to leverage the known effects of NO on ocular blood flow and the regulation of intraocular pressure homeostasis.
Please note: This information is generated by AI. For legal use, verify with company sources.
